Tourmaline Oil Corp. (TOU.TO)
| Previous Close | 21.05 |
| Open | 20.64 |
| Bid | 20.75 x 0 |
| Ask | 20.78 x 0 |
| Day's Range | 20.51 - 20.86 |
| 52 Week Range | 6.73 - 21.30 |
| Volume | 576,910 |
| Avg. Volume | 1,675,232 |
| Market Cap | 5.653B |
| Beta (5Y Monthly) | 1.74 |
| PE Ratio (TTM) | 111.61 |
| EPS (TTM) | 0.19 |
| Earnings Date | Mar. 01, 2021 - Mar. 05, 2021 |
| Forward Dividend & Yield | 0.56 (2.67%) |
| Ex-Dividend Date | Sep. 14, 2020 |
| 1y Target Est | 27.60 |
- CNW Group
Health Canada Approves IMBRUVICA®* (ibrutinib) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
Patients aged 70 or younger with previously untreated CLL lived longer without disease progression compared to patients treated with FCR, a chemoimmunotherapy regimenTORONTO, Jan. 13, 2021 /CNW/ - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has approved IMBRUVICA® (ibrutinib) in combination with rituximab for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL).
- The Motley Fool
Buy This 1 High-Quality Value Stock for a 2021 Recovery
Here’s why value investors bullish on a recovery in the latter half of 2021 have a quality pick in Tourmaline Oil (TSX:TOU).The post Buy This 1 High-Quality Value Stock for a 2021 Recovery appeared first on The Motley Fool Canada.
- Simply Wall St.
What Can We Learn About Tourmaline Oil's (TSE:TOU) CEO Compensation?
This article will reflect on the compensation paid to Mike Rose who has served as CEO of Tourmaline Oil Corp. ( TSE:TOU...
